Pacira Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2018 Annual Meeting of Stockholders held by Pacira Pharmaceuticals, Inc. on June 12, 2018, in Parsippany, New Jersey. The filing details the voting outcomes for three specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders approved all three proposals presented at the meeting:
- Proposal 1 (Election of Directors): Three Class I directors were elected to serve until the 2021 Annual Meeting.
- Laura Brege: 28,796,231 For; 5,296,103 Withheld.
- Mark I. Froimson: 34,031,497 For; 60,837 Withheld.
- Mark A. Kronenfeld: 34,031,833 For; 60,501 Withheld.
- Proposal 2 (Auditor Ratification): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- 36,929,562 For; 53,266 Against; 2,400 Abstain.
- Proposal 3 (Executive Compensation): The advisory vote to approve named executive officer compensation was approved.
- 32,005,700 For; 2,057,960 Against; 28,674 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote at the meeting to contextualize the "For" and "Withheld" vote counts.
- Confirm the specific terms of the Class I director elections and their tenure until 2021.
- Review the full proxy statement for details on the executive compensation package approved in Proposal 3.
- Note that 2,892,894 broker non-votes were recorded for the director election and executive compensation proposals.